Logo image of CY4.MI

CY4GATE SPA (CY4.MI) Stock Fundamental Analysis

Europe - Euronext Milan - BIT:CY4 - IT0005412504 - Common Stock

8.12 EUR
0 (0%)
Last: 12/12/2025, 7:00:00 PM
Fundamental Rating

3

Overall CY4 gets a fundamental rating of 3 out of 10. We evaluated CY4 against 113 industry peers in the Software industry. CY4 has a bad profitability rating. Also its financial health evaluation is rather negative. CY4 is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year CY4 has reported negative net income.
In the past year CY4 had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CY4 reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: CY4 reported negative operating cash flow in multiple years.
CY4.MI Yearly Net Income VS EBIT VS OCF VS FCFCY4.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

1.2 Ratios

CY4 has a worse Return On Assets (-9.06%) than 78.76% of its industry peers.
With a Return On Equity value of -18.20%, CY4 is not doing good in the industry: 74.34% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -9.06%
ROE -18.2%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CY4.MI Yearly ROA, ROE, ROICCY4.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

The Gross Margin of CY4 (43.51%) is worse than 74.34% of its industry peers.
CY4's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CY4 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 43.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.65%
GM growth 5Y-0.54%
CY4.MI Yearly Profit, Operating, Gross MarginsCY4.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

3

2. Health

2.1 Basic Checks

CY4 does not have a ROIC to compare to the WACC, probably because it is not profitable.
CY4 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CY4.MI Yearly Shares OutstandingCY4.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
CY4.MI Yearly Total Debt VS Total AssetsCY4.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

CY4 has an Altman-Z score of 1.53. This is a bad value and indicates that CY4 is not financially healthy and even has some risk of bankruptcy.
CY4 has a Altman-Z score of 1.53. This is in the lower half of the industry: CY4 underperforms 65.49% of its industry peers.
CY4 has a debt to FCF ratio of 3.47. This is a good value and a sign of high solvency as CY4 would need 3.47 years to pay back of all of its debts.
CY4 has a Debt to FCF ratio (3.47) which is comparable to the rest of the industry.
CY4 has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.23, CY4 is in line with its industry, outperforming 56.64% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 3.47
Altman-Z 1.53
ROIC/WACCN/A
WACC8.52%
CY4.MI Yearly LT Debt VS Equity VS FCFCY4.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

CY4 has a Current Ratio of 1.32. This is a normal value and indicates that CY4 is financially healthy and should not expect problems in meeting its short term obligations.
CY4's Current ratio of 1.32 is in line compared to the rest of the industry. CY4 outperforms 45.13% of its industry peers.
CY4 has a Quick Ratio of 1.29. This is a normal value and indicates that CY4 is financially healthy and should not expect problems in meeting its short term obligations.
CY4 has a Quick ratio (1.29) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 1.29
CY4.MI Yearly Current Assets VS Current LiabilitesCY4.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

6

3. Growth

3.1 Past

CY4 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.22%, which is quite impressive.
The Revenue has grown by 28.46% in the past year. This is a very strong growth!
CY4 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 59.24% yearly.
EPS 1Y (TTM)41.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.13%
Revenue 1Y (TTM)28.46%
Revenue growth 3Y61.94%
Revenue growth 5Y59.24%
Sales Q2Q%32.24%

3.2 Future

The Earnings Per Share is expected to grow by 33.72% on average over the next years. This is a very strong growth
Based on estimates for the next years, CY4 will show a quite strong growth in Revenue. The Revenue will grow by 9.12% on average per year.
EPS Next Y17.64%
EPS Next 2Y38.05%
EPS Next 3Y33.72%
EPS Next 5YN/A
Revenue Next Year13.24%
Revenue Next 2Y10.38%
Revenue Next 3Y9.12%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CY4.MI Yearly Revenue VS EstimatesCY4.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
CY4.MI Yearly EPS VS EstimatesCY4.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CY4. In the last year negative earnings were reported.
Also next year CY4 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CY4.MI Price Earnings VS Forward Price EarningsCY4.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CY4 is valued a bit more expensive than the industry average as 61.06% of the companies are valued more cheaply.
Based on the Price/Free Cash Flow ratio, CY4 is valued cheaper than 82.30% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.88
EV/EBITDA 53.31
CY4.MI Per share dataCY4.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

A more expensive valuation may be justified as CY4's earnings are expected to grow with 33.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.05%
EPS Next 3Y33.72%

0

5. Dividend

5.1 Amount

No dividends for CY4!.
Industry RankSector Rank
Dividend Yield 0%

CY4GATE SPA

BIT:CY4 (12/12/2025, 7:00:00 PM)

8.12

0 (0%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners12.74%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap191.39M
Revenue(TTM)113.27M
Net Income(TTM)-16.38M
Analysts86.67
Price Target6.73 (-17.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP2.35%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.09%
PT rev (3m)13.79%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)5.3%
EPS NY rev (3m)-63.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.69
P/FCF 16.88
P/OCF 14.18
P/B 2.13
P/tB 14.8
EV/EBITDA 53.31
EPS(TTM)-0.66
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)0.48
FCFY5.92%
OCF(TTM)0.57
OCFY7.05%
SpS4.81
BVpS3.82
TBVpS0.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -9.06%
ROE -18.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 43.51%
FCFM 10.01%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.65%
GM growth 5Y-0.54%
F-Score5
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF 3.47
Debt/EBITDA 5.15
Cap/Depr 9.94%
Cap/Sales 1.91%
Interest Coverage N/A
Cash Conversion 330.53%
Profit Quality N/A
Current Ratio 1.32
Quick Ratio 1.29
Altman-Z 1.53
F-Score5
WACC8.52%
ROIC/WACCN/A
Cap/Depr(3y)19.8%
Cap/Depr(5y)17.04%
Cap/Sales(3y)4.99%
Cap/Sales(5y)3.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.13%
EPS Next Y17.64%
EPS Next 2Y38.05%
EPS Next 3Y33.72%
EPS Next 5YN/A
Revenue 1Y (TTM)28.46%
Revenue growth 3Y61.94%
Revenue growth 5Y59.24%
Sales Q2Q%32.24%
Revenue Next Year13.24%
Revenue Next 2Y10.38%
Revenue Next 3Y9.12%
Revenue Next 5YN/A
EBIT growth 1Y16.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2716.67%
EBIT Next 3Y245.52%
EBIT Next 5YN/A
FCF growth 1Y57.74%
FCF growth 3YN/A
FCF growth 5Y87.64%
OCF growth 1Y25.87%
OCF growth 3YN/A
OCF growth 5Y43.36%

CY4GATE SPA / CY4.MI FAQ

Can you provide the ChartMill fundamental rating for CY4GATE SPA?

ChartMill assigns a fundamental rating of 3 / 10 to CY4.MI.


What is the valuation status of CY4GATE SPA (CY4.MI) stock?

ChartMill assigns a valuation rating of 2 / 10 to CY4GATE SPA (CY4.MI). This can be considered as Overvalued.


Can you provide the profitability details for CY4GATE SPA?

CY4GATE SPA (CY4.MI) has a profitability rating of 1 / 10.


What is the financial health of CY4GATE SPA (CY4.MI) stock?

The financial health rating of CY4GATE SPA (CY4.MI) is 3 / 10.